MX2012003547A - Combinacion. - Google Patents

Combinacion.

Info

Publication number
MX2012003547A
MX2012003547A MX2012003547A MX2012003547A MX2012003547A MX 2012003547 A MX2012003547 A MX 2012003547A MX 2012003547 A MX2012003547 A MX 2012003547A MX 2012003547 A MX2012003547 A MX 2012003547A MX 2012003547 A MX2012003547 A MX 2012003547A
Authority
MX
Mexico
Prior art keywords
methyl
human
pharmaceutically acceptable
acceptable salt
relates
Prior art date
Application number
MX2012003547A
Other languages
English (en)
Inventor
Melissa Dumble
Tona Gilmer
Rakesh Kumar
Peter F Lebowitz
Shannon Renae Morris
Sylvie Laquerre
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of MX2012003547A publication Critical patent/MX2012003547A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a un método de tratamiento del cáncer en un humano y a combinaciones farmacéuticas útiles en dicho tratamiento; en articular, el método se refiere a un método de tratamiento del cáncer que incluye administrar N-{3-[3-ciclopropil-5(2-fluoro-4-yodo-fenilamino)-6,8-dimetil-2,4 ,7-trioxo-3,4,6,7-tetrahidro-2H-pirido[4,3-d]pirimidin-1-il]fenil }acetamida, o una sal o solvato farmacéuticamente aceptable de la misma, y N-{(1S)-2-amino-1-[(3-fluorofenil)metil]etil}-5-cloro-4-( 4-cloro-1-metil-1H-pirazol-5-il)-2-tiofenocarboxamida, o una sal farmacéuticamente aceptable de la misma, a un humano en necesidad de dicho tratamiento.
MX2012003547A 2009-09-23 2010-09-23 Combinacion. MX2012003547A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24502709P 2009-09-23 2009-09-23
PCT/US2010/049952 WO2011038085A1 (en) 2009-09-23 2010-09-23 Combination

Publications (1)

Publication Number Publication Date
MX2012003547A true MX2012003547A (es) 2012-04-30

Family

ID=43796199

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012003547A MX2012003547A (es) 2009-09-23 2010-09-23 Combinacion.

Country Status (15)

Country Link
US (4) US20120283278A1 (es)
EP (1) EP2480085B1 (es)
JP (2) JP5890310B2 (es)
KR (1) KR101739158B1 (es)
CN (1) CN102762098B (es)
AU (1) AU2010298280B2 (es)
BR (1) BR112012006485A2 (es)
CA (1) CA2775125C (es)
EA (2) EA201270453A1 (es)
ES (1) ES2527831T3 (es)
IL (1) IL218801A (es)
MX (1) MX2012003547A (es)
SG (1) SG179144A1 (es)
WO (1) WO2011038085A1 (es)
ZA (1) ZA201201940B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
EP2913048A1 (en) 2014-02-27 2015-09-02 ratiopharm GmbH Pharmaceutical composition comprising trametinib

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
MXPA06014478A (es) 2004-06-11 2007-03-21 Japan Tobacco Inc Derivados de 5-amino-2, 4, 7-trioxo-3, 4, 7, 8-tetrahidro -2h-pirido[2, 3-d]pirimidina y compuestos relacionados para el tratamiento del cancer.
JP3821154B1 (ja) * 2005-03-16 2006-09-13 いすゞ自動車株式会社 排気ガス浄化方法及び排気ガス浄化システム
UY30892A1 (es) * 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt

Also Published As

Publication number Publication date
US20160143913A1 (en) 2016-05-26
CN102762098A (zh) 2012-10-31
EP2480085A1 (en) 2012-08-01
BR112012006485A2 (pt) 2015-09-08
EA201270453A1 (ru) 2013-12-30
JP2016104765A (ja) 2016-06-09
US20180214451A1 (en) 2018-08-02
CA2775125A1 (en) 2011-03-31
US20140309243A1 (en) 2014-10-16
CN102762098B (zh) 2015-10-14
WO2011038085A1 (en) 2011-03-31
EP2480085A4 (en) 2013-03-27
JP5890310B2 (ja) 2016-03-22
EA201500882A1 (ru) 2016-05-31
AU2010298280A1 (en) 2012-04-05
ES2527831T3 (es) 2015-01-30
US20120283278A1 (en) 2012-11-08
JP6148320B2 (ja) 2017-06-14
IL218801A0 (en) 2012-06-28
IL218801A (en) 2015-03-31
EP2480085B1 (en) 2014-11-12
KR101739158B1 (ko) 2017-05-23
JP2013505940A (ja) 2013-02-21
AU2010298280B2 (en) 2014-07-03
SG179144A1 (en) 2012-05-30
CA2775125C (en) 2019-01-08
ZA201201940B (en) 2012-11-28
KR20120099218A (ko) 2012-09-07

Similar Documents

Publication Publication Date Title
IL206296A (en) History of aminopyrazole, and their medicinal products and their use in the preparation of drugs for the prevention and treatment of diseases
UA92584C2 (ru) Применение мелоксикама для лечения респираторных заболеваний у свиней
IL191984A0 (en) Isoquinoline aminopyrazole derivatives, their manufacture and use as pharmaceutical agents for the treatment of cancer
PH12016500499B1 (en) Therapeutic polymeric nanoparticles and methods of making and using same
JO3594B1 (ar) تركيبة صيدلانية جديدة
PT2210588E (pt) Composição expansível, essencialmente isenta de ingredientes farmaceuticamente activos para o tratamento da pele humana
WO2008131057A3 (en) Sustained release formulations of opioid and nonopioid analgesics
IL232764A (en) Fluoromethyl6,5 - Dihydro - 4 H - [3,1] Oxazines, Pharmaceuticals Containing Them and Their Use in the Preparation of Medicines to Treat Alzheimer's Disease
MX2016010179A (es) Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer.
EP2415478A4 (en) PROPHYLAXIS OR THERAPY AGENTS FOR KIDNEY DISEASES AND METHODS OF PREVENTING OR TREATING NURSE DISEASES, EACH OF THEM WITH A JNK (C-JUN-N-TERMINAL KINASE) -IMBING PEPTIDE, AND USE OF THE PEPTIDE
HK1137352A1 (en) Therapeutic use of at least one botulic neurotoxin in the treatment of pain induced by at least one antineoplastic agent
IL215826A (en) Pharmaceutical preparation with delayed release, process of preparation of the preparation, use of the preparation for the preparation of pain medication and the pill containing it.
MX2021002321A (es) Nuevos metodos.
MX2013008074A (es) Combinacion.
MY156302A (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF ß-AMYLOID DISEASES AND SYNUCLEINOPATHIES
BRPI0610780A2 (pt) formulação farmacéutica em tablete desintegrante, e, métodos para tratar um paciente em necessidade de tratamento com olanzapina, e para produzir a formulação farmacêutica em tablete
EA201270445A1 (ru) Комбинация
TN2015000198A1 (en) Novel pharmaceutical composition
IN2015DN02667A (es)
NZ596226A (en) Antitumor combination including cabazitaxel and capecitabine
MX2012003547A (es) Combinacion.
PL2640364T3 (pl) Kompozycja farmaceutyczna zawierająca sól wodorowęglanową i jej zastosowanie jako leku w leczeniu i/lub profilaktyce kamicy moczowej i chorób pokrewnych
EP1924286A4 (en) PROPHYLACTIC AND / OR THERAPEUTIC METHOD FOR THE TREATMENT OF AUTOIMMUNE DISEASES
EP2711374A4 (en) NOVEL METALLOPROTEIN AND PROCESS FOR PRODUCTION THEREOF, AND PROPHYLACTIC OR THERAPEUTIC AGENT FOR CORNEAL AND CONJUNCTIVE DISEASES COMPRISING SAID METALLOPROTEIN
PL1781292T3 (pl) Formulacja o przedłużonym uwalnianiu 3-amino-8-(1-piperazynylo)-2H-1-benzopiran-2-onu

Legal Events

Date Code Title Description
FG Grant or registration